Nasdaq · Healthcare

Aclaris Therapeutics, Inc. (ACRS)

As-reported financials and recent SEC filings for Aclaris Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$7.8M

Net income

$-64.9M

Net margin

—

Diluted EPS

$-0.53

ROE

-63.0%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$7.8M	$18.7M	$31.2M	$29.8M	$6.8M
Gross profit	$5.7M	$15.9M	$27.8M	$25.7M	$2.0M
Operating income	$-76.4M	$-141.9M	$-97.4M	$-89.9M	$-89.7M
Net income	$-64.9M	$-132.1M	$-88.5M	$-86.9M	$-90.9M
Diluted EPS	$-0.53	$-1.71	$-1.27	$-1.33	$-1.60

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-06-08

42026-06-08

42026-06-08

42026-06-08

42026-06-08

42026-06-08

8-K2026-06-04

SCHEDULE 13G/A2026-05-12

View on EDGAR →

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on ACRS

Search Aclaris Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.